Teriflunomide for the treatment of relapsing–remitting multiple sclerosis

References

• Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-17
   PubMed Web of Science ®Google Scholar
• Gold R, Wolinsky JS. Pathophysiology of multiple sclerosis and the place of teriflunomide. Acta Neurol Scand 2011;124:75-84
   PubMed Web of Science ®Google Scholar
• Tremlett H, Yousefi M, Devonshire V, et al. Impact of multiple sclerosis relapses on progression diminishes with time. Neurology 2009;73:1616-23
   PubMed Web of Science ®Google Scholar
• Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 2010;133(Pt 7):1914-29
   PubMed Web of Science ®Google Scholar
• World Health Organization. Atlas: multiple sclerosis resources in the world. World Health Organization; Geneva, Switzerland: ed. 2008
   Google Scholar
• PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-94
   PubMed Web of Science ®Google Scholar
• The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268-76
   PubMed Web of Science ®Google Scholar
• Reuss R. PEGylated interferon beta-1a in the treatment of multiple sclerosis – an update. Biologics 2013;7:131-8
   PubMedGoogle Scholar
• US Prescribing Information: copaxone, Teva Neuroscience, 2014. Available from: www.copaxone.com/Resources/pdfs/PrescribingInformation.pdf [Last accessed 24 September 2014]
   Google Scholar
• Caporro M, Disanto G, Gobbi C, Zecca C. Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing-remitting multiple sclerosis treatment. Patient Prefer Adherence 2014;8:1123-34
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401
   PubMed Web of Science ®Google Scholar
• Efficacy and safety of fingolimod in patients with relapsing-remitting multiple sclerosis with optional extension phase (TRANSFORMS). Available from: http://clinicaltrials.gov/show/NCT00340834
   Google Scholar
• Efficacy and safety of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS). Available from: http://clinicaltrials.gov/show/NCT00289978
   Google Scholar
• Summary of Product Characteristics: gilenya, Novartis, 2014. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002202/WC500104528.pdf [Last accessed 24 September 2014]
   Google Scholar
• Selmaj K, Vollmer T, Bar-Or A, on behalf of the DreaMS study investigators. Effect of ONO-4641, a potent, oral, selective sphingosine-1-phosphate receptor-1 and -5 agonist, on MRI outcomes in patients with relapsing remitting multiple sclerosis: subgroup analyses from the phase 2 DreaMS study. Mult Scler 2013;19:74-558. P536
   Google Scholar
• A Study of the safety and efficacy of ONO-4641 in patients with relapsing-remitting multiple sclerosis (DreaMS). Available from: http://clinicaltrials.gov/show/NCT01081782
   Google Scholar
• Pozzilli C FO, Olsson T, Freedman MS, et al. Maintenance of efficacy, safety and tolerability of ponesimod in patients with relapsing remitting multiple sclerosis: phase II extension study. Mult Scler 2013;19:74-558. P995
   Google Scholar
• Ponesimod in patients with relapsing-remitting multiple sclerosis -extension study. Available from: http://clinicaltrials.gov/show/NCT01093326
   Google Scholar
• Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND), 2014. Available from: https://clinicaltrials.gov/ct2/show/NCT01665144?term=NCT01665144&rank=1 [Last accessed 24 September 2014]
   Google Scholar
• Linker RA, Lee DH, Ryan S, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011;134(Pt 3):678-92
   PubMed Web of Science ®Google Scholar
• Scannevin RH, Chollate S, Jung MY, et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther 2012;341:274-84
   PubMed Web of Science ®Google Scholar
• Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97
   PubMed Web of Science ®Google Scholar
• Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107
   PubMed Web of Science ®Google Scholar
• Efficacy and safety study of oral BG00012 with active reference in relapsing-remitting multiple sclerosis (CONFIRM). Available from: http://clinicaltrials.gov/show/NCT00451451
   Google Scholar
• Efficacy and safety of oral BG00012 in relapsing-remitting multiple sclerosis (DEFINE). Available from: http://clinicaltrials.gov/show/NCT00420212
   Google Scholar
• Summary of Product Characteristics: tecfidera, Biogen Idec Ltd, 2014. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002601/WC500162069.pdf [Last accessed 14 October 2014]
   Google Scholar
• Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
   PubMed Web of Science ®Google Scholar
• Safety and efficacy of natalizumab in the treatment of multiple sclerosis. Available from: http://clinicaltrials.gov/show/NCT00027300
   Google Scholar
• Summary of Product Characteristics: tysabri, Biogen Idec Ltd, 2014. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000603/WC500044686.pdf [Last accessed 14 October 2014]
   Google Scholar
• Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012;380:1819-28
   PubMed Web of Science ®Google Scholar
• Comparison of alemtuzumab and Rebif® efficacy in multiple sclerosis, study one (CARE-MS I). Available from: http://clinicaltrials.gov/show/NCT00530348
   Google Scholar
• Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012;380:1829-39
   PubMed Web of Science ®Google Scholar
• Comparison of alemtuzumab and Rebif® efficacy in multiple sclerosis, study two (CARE-MS II). Available from: http://clinicaltrials.gov/show/NCT00548405
   Google Scholar
• An extension protocol for multiple sclerosis patients who participated in Genzyme-sponsored studies of alemtuzumab. Available from: http://clinicaltrials.gov/show/NCT00930553
   Google Scholar
• Havrdova E, Arnold DL, Palmer J, Margolin DH. Disease-free outcomes with alemtuzumab: 3-year follow-up of the CARE-MS studies. Mult Scler J 2014;20(Suppl 1):39
   Google Scholar
• Summary of product characteristics: lemtrada, Genzyme 2014. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003718/WC500150521.pdf [Last accessed 14 October 2014]
   Google Scholar
• Safety and efficacy study of daclizumab high yield process (DAC HYP) to treat relapsing-remitting multiple sclerosis (SELECT). Available from: http://clinicaltrials.gov/show/NCT00390221
   Google Scholar
• Gold R, Giovannoni G, Selmaj K, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet 2013;381:2167-75
   PubMed Web of Science ®Google Scholar
• Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011;378:1779-87
   PubMed Web of Science ®Google Scholar
• A study of the efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis. Available from: http://clinicaltrials.gov/show/NCT00676715
   Google Scholar
• Sorensen PS, Lisby S, Grove R, et al. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study. Neurology 2014;82:573-81
   PubMed Web of Science ®Google Scholar
• Ofatumumab subcutaneous administration in subjects with relapsing-remitting multiple sclerosis (MIRROR). Available from: http://clinicaltrials.gov/show/NCT01457924
   Google Scholar
• Bar-Or A, Grove R, Austin D, et al. The MIRROR Study: a Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the Safety and MRI Efficacy of Subcutaneous Ofatumumab in Subjects with Relapsing-Remitting Multiple Sclerosis (RRMS). Neurology 2014;82(Suppl 10):S23.006
   Google Scholar
• Sorenson PS, Kavanagh ST, Austin DJ, et al. Follow-up data from the Mirror study: a dose-ranging study of subcutaneous ofatumumab in subjects with relapsing-remitting multiple sclerosis. Mult Scler J 2014;20(Suppl 1):67-284. P048
   PubMedGoogle Scholar
• Pepinsky RB, Shao Z, Ji B, et al. Exposure levels of anti-LINGO-1 Li81 antibody in the central nervous system and dose-efficacy relationships in rat spinal cord remyelination models after systemic administration. J Pharmacol Exp Ther 2011;339:519-29
   PubMed Web of Science ®Google Scholar
• BIIB033 single ascending dose study in healthy volunteer subjects. Available from: http://clinicaltrials.gov/show/NCT01052506
   Google Scholar
• Safety study of BIIB033 in subjects with multiple sclerosis. Available from: http://clinicaltrials.gov/show/NCT01244139
   Google Scholar
• Tran J PR, Zhao J, Brosofsky K, et al. Safety, tolerability and pharmacokinetics of the anti-LINGO-1 monoclonal antibody BIIB033 in healthy volunteers and subjects with multiple sclerosis. Neurology 2012;78:P02.021
   Google Scholar
• Rivera VM, Jeffery DR, Weinstock-Guttman B, et al. Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study. BMC Neurol 2013;13:80
   PubMed Web of Science ®Google Scholar
• Martinelli V, Radaelli M, Straffi L, et al. Mitoxantrone: benefits and risks in multiple sclerosis patients. Neurol Sci 2009;30(Suppl 2):S167-70
   Google Scholar
• US prescribing information: Aubagio, Sanofi. Available from. http://products.sanofi.us/aubagio/aubagio.pdf [Last accessed 14 October 2014]
   Google Scholar
• EU Summary of product characteristics: Aubagio, Sanofi-Aventis. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002514/WC500148682.pdf [Last accessed 14 October 2014]
   Google Scholar
• EU Summary of product characteristics: arava, Sanofi-Aventis. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000235/WC500026289.pdf [Last accessed 14]
   Google Scholar
• Bar-Or A, Pachner A, Menguy-Vacheron F, et al. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs 2014;74:659-74
   PubMed Web of Science ®Google Scholar
• Li L, Liu J, Delohery T, et al. The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells in vitro. J Neuroimmunol 2013;265:82-90
   PubMed Web of Science ®Google Scholar
• Merrill JE, Hanak S, Pu SF, et al. Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the dark agouti rat model of experimental autoimmune encephalomyelitis. J Neurol 2009;256:89-103
   PubMed Web of Science ®Google Scholar
• Ringheim GE, Lee L, Laws-Ricker L, et al. Teriflunomide attenuates immunopathological changes in the dark agouti rat model of experimental autoimmune encephalomyelitis. Front Neurol 2013;4:169
   PubMedGoogle Scholar
• Petty M, Lee L, Ying X, et al. Teriflunomide treatment reduces infiltration of macrophages, T cells and B cells, and increases survival of oligodendrocytes in the spinal cord of the dark agouti rat model of experimental allergic encephalomyelitis. Neurology 2010;74:P05.033
   Google Scholar
• Iglesias-Bregna D, Hanak S, Ji Z, et al. Effects of prophylactic and therapeutic teriflunomide in transcranial magnetic stimulation-induced motor-evoked potentials in the dark agouti rat model of experimental autoimmune encephalomyelitis. J Pharmacol Exp Ther 2013;347:203-11
   PubMed Web of Science ®Google Scholar
• Pachner A, Li L. Teriflunomide ameliorates disability progression in the Theiler’s virus-induced demyelinating disease model of MS. Presented at AAN Annual Meeting, San Diego, CA, USA; 16-23 March 2013 P05.196
   Google Scholar
• Wolinsky J, Dukovic D, Truffinet P, Kappos L. Estimating the onset of efficacy with teriflunomide in patients with relapsing forms of multiple sclerosis. Neurology 2014;82(Suppl 10):P7.214
   Google Scholar
• Freedman MS. Teriflunomide in relapsing multiple sclerosis: therapeutic utility. Ther Adv Chronic Dis 2013;4:192-205
   PubMedGoogle Scholar
• Safety and efficacy of teriflunomide (HMR1726) in multiple sclerosis with relapses. Available from: http://clinicaltrials.gov/show/NCT01487096
   Google Scholar
• O’Connor PW, Li D, Freedman MS, et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006;66:894-900
   PubMed Web of Science ®Google Scholar
• Li DBK, Traboulsee AL, Truffinet P, et al. Long-term MRI outcomes from patients treated with teriflunomide: results from a phase 2 extension study. Mult Scler J 2014;20:67-284. P079
   PubMedGoogle Scholar
• Long term safety and efficacy of teriflunomide (HMR1726) in multiple sclerosis with relapses. Available from: http://clinicaltrials.gov/show/NCT00228163
   Google Scholar
• Confavreux C, Li DK, Freedman MS, et al. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult Scler 2012;18:1278-89
   PubMed Web of Science ®Google Scholar
• Study of teriflunomide in reducing the frequency of relapses and accumulation of disability in patients with multiple sclerosis (TEMSO). Available from: http://clinicaltrials.gov/show/NCT00134563
   Google Scholar
• O’Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011;365:1293-303
   PubMed Web of Science ®Google Scholar
• Wolinsky JS, Narayana PA, Nelson F, et al. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. Mult Scler 2013;19:1310-19
   PubMed Web of Science ®Google Scholar
• Long term safety and efficacy study of teriflunomide 7 mg or 14 mg in patients with relapsing-remitting multiple sclerosis. Available from: http://clinicaltrials.gov/show/NCT00803049
   Google Scholar
• Freedman M Wolinsky J, Comi G, et al. Safety and Efficacy of Teriflunomide for up to 9 Years in Relapsing Forms of Multiple Sclerosis: update of the TEMSO Extension Trial. Neurology 2014;82(Suppl 10):P3.150
   Google Scholar
• O’Connor PW, Lublin FD, Wolinsky JS, et al. Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use. J Neurol 2013;260:2472-80
   PubMed Web of Science ®Google Scholar
• Miller AE, O’Connor P, Wolinsky JS, et al. Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Mult Scler 2012;18:1625-32
   PubMed Web of Science ®Google Scholar
• An efficacy study of teriflunomide in patients with relapsing multiple sclerosis (TOWER). Available from: http://clinicaltrials.gov/ct2/show/NCT00751881
   Google Scholar
• Confavreux C, O’Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2014;13:247-56
   PubMed Web of Science ®Google Scholar
• Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial. Neurology 2002;59:1496-506
   PubMed Web of Science ®Google Scholar
• Miller AE, Macdonell R, Comi G, et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. J Neurol 2014;261:1781-8
   PubMed Web of Science ®Google Scholar
• Moses H, Freedman MS, Kappos L, et al. Pre-defined subgroups analyses of TOWER, a placebo-controlled phase III trial of teriflunomide in patients with relapsing multiple sclerosis. Neurology 2013;80:S41.006
   Google Scholar
• Kappos L, Comi G, Freedman MS, et al. Pooled efficacy data from two phase 3 placebo-controlled trials of oral, once-daily teriflunomide. Mult Scler J 2013;19(Suppl 1):74-558. P618
   Google Scholar
• A study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosis (TENERE). Available from: http://clinicaltrials.gov/show/NCT00883337
   Google Scholar
• Vermersch P, Czlonkowska A, Grimaldi LM, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler J 2014;20:705-16
   PubMed Web of Science ®Google Scholar
• Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2004;2:12
   PubMedGoogle Scholar
• Phase III study with teriflunomide versus placebo in patients with first clinical symptom of multiple sclerosis (TOPIC). Available from: http://clinicaltrials.gov/show/NCT00622700
   Google Scholar
• Miller AE, Wolinsky JS, Kappos L, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2014;13:977-86
   PubMed Web of Science ®Google Scholar
• Phase II study of teriflunomide as adjunctive therapy to interferon-beta in subjects with multiple sclerosis. Available from: http://clinicaltrials.gov/show/NCT00489489
   Google Scholar
• Freedman MS, Wolinsky JS, Wamil B, et al. Teriflunomide added to interferon-beta in relapsing multiple sclerosis: a randomized phase II trial. Neurology 2012;78:1877-85
   PubMed Web of Science ®Google Scholar
• Long term safety of teriflunomide when added to interferon-beta or glatiramer acetate in patients with multiple sclerosis. Available from: http://clinicaltrials.gov/show/NCT00811395
   Google Scholar
• Phase II study of teriflunomide as adjunctive therapy to glatiramer acetate in subjects with multiple sclerosis. Available from: http://clinicaltrials.gov/show/NCT00475865
   Google Scholar
• Freedman MS, Wolinsky J, Wamil B, et al. for the Teriflunomide Multiple Sclerosis Trial Group. Oral teriflunomide plus glatiramer acetate in relapsing multiple sclerosis. Int J MS Care 2011;13(Suppl 3):P17
   Google Scholar
• Efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis and treated with interferon-beta (TERACLES). Available from: http://clinicaltrials.gov/show/NCT01252355
   Google Scholar
• Freedman MS, Wolinsky J, Comi G, et al. for the TERACLES Study Group. Safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis treated with interferon beta. 8th World Congress on Controversies in Neurology, 2014. Available from: www.comtecmed.com/cony/2014/Uploads/Editor/Freedman.pdf [Last accessed 14 October 2014]
   Google Scholar
• Study to investigate the immune response to influenza vaccine in patients with multiple sclerosis on teriflunomide (TERIVA). Available from: http://clinicaltrials.gov/show/NCT01403376
   Google Scholar
• Bar-Or A, Freedman MS, Kremenchutzky M, et al. Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis. Neurology 2013;81:552-8
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Larouche R, Legrand B, et al. Immune response to neoantigen and recall antigens in healthy subjects receiving teriflunomide. Mult Scler 2013;19(Suppl 1):74-558. P622
   Google Scholar
• Comi G, Freedman MS, Kappos L, et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER Study. J Neurol Sci 2013;333:e376
   Google Scholar
• Leist TP, Freedman MS, Kappos L, et al. Pooled safety analyses from the teriflunomide clinical development program. Mult Scler J 2014;20(Suppl 1):67-284. P097
   PubMedGoogle Scholar
• Kieseier B, Truffinet P, Jung Henson L. Pregnancy outcomes for female patients and partners of male patients in the teriflunomide clinical development program. Mult Scler J 2014;20(Suppl 1):285-496. P846
   PubMedGoogle Scholar
• Jung Henson L, Benamor M, Truffinet P, Kieseier B. Updated pregnancy outcomes in patients and partners of patients in the teriflunomide clinical trial program. Neurology 2014;82(Suppl 10):P4.161
   Google Scholar
• Garcia-Enguidanos A, Calle ME, Valero J, et al. Risk factors in miscarriage: a review. Eur J Obstet Gynecol Reprod Biol 2002;102:111-19
   PubMed Web of Science ®Google Scholar
• Davenport L, Czich A, Turpaul S. Teriflunomide: non-clinical evaluation demonstrates no effect on sperm DNA or male fertility. Neurology 2014;82(Suppl 10):P2.233
   Google Scholar
• Chambers CD, Johnson DL, Robinson LK, et al. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum 2010;62:1494-503
   PubMed Web of Science ®Google Scholar
• Sajja BR, Datta S, He R, et al. Unified approach for multiple sclerosis lesion segmentation on brain MRI. Ann Biomed Eng 2006;34:142-51
   PubMedGoogle Scholar